Supplementary Figure1: A forest plot of the change in FENO (ppb) at week 12.



Supplementary Figures 2A: A forest plot of the change in FENO (ppb) at week 24.



Supplementary Figures 2B: A forest plot of the change in FENO (ppb) at week 24 after sensitivity analysis.



Supplementary Figure 3: A forest plot of the change in blood eosinophils (cells/mm^3) at week 12.



Supplementary Figure 4: A forest plot of the change in blood eosinophils (cells/mm^3) at week 24.



Supplementary Figure 5: A forest plot of the change in IgE (IU/mL) at week 12.



Supplementary Figure 6: A forest plot of the change in IgE (IU/mL) at week 24.



Supplementary Figure 7: A forest plot of any and treatment-emergent adverse events.



Supplementary Figure 8: A forest plot of any and treatment-emergent adverse events leading to permanent discontinuation.



Supplementary Figure 9: A forest plot of serious and treatment-emergent adverse events.



Supplementary Figure 10: A forest plot of any adverse events leading to death and any treatment-emergent adverse events leading to death.



Supplementary Figure 11: A forest plot of upper respiratory tract infection, viral upper respiratory tract infection, and influenza adverse events.



Supplementary Figure 12: A forest plot of nasopharyngitis, sinusitis, and bronchitis adverse events.



Supplementary Figure 13: A forest plot of injection site reaction, eosinophilia, and headache adverse events.



Supplementary Figure 14: A forest plot of allergic rhinitis, cough, urinary tract infection, back pain, and erythema adverse events.